Recursion Pharma Q4 revenue tops eatimates, helped by Sanofi payments

Recursion Pharmaceuticals

25/02/2026 11:44

Overview

Clinical stage TechBio firm's Q4 operating revenue beat analyst expectations

Net income for Q4 exceeded analyst estimates

Company achieved milestone payment from Sanofi, totaling $134 mln to date

Outlook

Recursion expects cash runway to extend into early 2028 without additional financing

Company anticipates milestone payments as Sanofi programs advance in next 12-18 months

Recursion plans FDA engagement for REC-4881 in 1H26 to discuss registration pathway

Result Drivers

AI OPERATING SYSTEM VALIDATION - Recursion achieved first clinical validation of its AI Operating System in FAP, demonstrating translation from AI-driven biological insight to patient outcomes

SANOFI MILESTONE PAYMENTS - Recursion received $134 mln in milestone payments from Sanofi, reflecting progress in AI-driven small molecule programs

COST MANAGEMENT - Exceeded original cost savings guidance, extending cash runway into early 2028 without additional financing

Company press release: ID:nGNX6FGL8n

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Operating Revenue
Beat
$35.35 mln
$24.59 mln (7 Analysts)
Q4 Net Income
Beat
-$108.12 mln
-$131.06 mln (5 Analysts)
Q4 Pretax Profit
Beat
-$108.10 mln
-$113.87 mln (3 Analysts)
Q4 Operating Income
-$108.34 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Recursion Pharmaceuticals Inc is $7.00, about 98.3% above its February 24 closing price of $3.53

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)